AU2021338361A1 - Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs - Google Patents

Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs Download PDF

Info

Publication number
AU2021338361A1
AU2021338361A1 AU2021338361A AU2021338361A AU2021338361A1 AU 2021338361 A1 AU2021338361 A1 AU 2021338361A1 AU 2021338361 A AU2021338361 A AU 2021338361A AU 2021338361 A AU2021338361 A AU 2021338361A AU 2021338361 A1 AU2021338361 A1 AU 2021338361A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
identity
amino acid
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021338361A
Other languages
English (en)
Inventor
Jeffrey S. Bartlett
Louis Randall Breton
Irvin S.Y. Chen
Ming Yan
Anjie ZHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chen Irvin SY
Rampart Bioscience Inc
University of California, San Diego
Original Assignee
Rampart Bioscience Inc
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rampart Bioscience Inc, University of California Berkeley, University of California, San Diego filed Critical Rampart Bioscience Inc
Publication of AU2021338361A1 publication Critical patent/AU2021338361A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2021338361A 2020-09-03 2021-09-02 Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs Pending AU2021338361A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074418P 2020-09-03 2020-09-03
US63/074,418 2020-09-03
PCT/US2021/048943 WO2022051555A2 (en) 2020-09-03 2021-09-02 Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs

Publications (1)

Publication Number Publication Date
AU2021338361A1 true AU2021338361A1 (en) 2023-04-06

Family

ID=78676616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021338361A Pending AU2021338361A1 (en) 2020-09-03 2021-09-02 Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs

Country Status (8)

Country Link
US (1) US20240150737A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203989A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023540098A (cg-RX-API-DMAC7.html)
KR (1) KR20230117327A (cg-RX-API-DMAC7.html)
CN (1) CN116848146A (cg-RX-API-DMAC7.html)
AU (1) AU2021338361A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190513A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022051555A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
WO2025090786A1 (en) * 2023-10-24 2025-05-01 Rampart Bioscience, Inc. Reduced immunogenic gene therapy protocols using circular, extended cruciform containing non-viral vectors
WO2025097067A2 (en) * 2023-11-02 2025-05-08 Be Biopharma, Inc. Engineered cell preparations for treatment of hypophosphatasia
AU2024407494A1 (en) * 2023-12-19 2026-07-23 Evotec International Gmbh Plasmids, transgenes, vectors and medical uses comprising tissue non-specific alkaline phosphatase
WO2026089719A1 (en) * 2024-10-24 2026-04-30 Rampart Bioscience, Inc. Dna vectors having specialized secondary structures for use in treating hypophosphatasia

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
GB0024827D0 (en) * 2000-10-10 2000-11-22 Norwegian Inst Of Fisheries & Product
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7510877B2 (en) 2003-09-26 2009-03-31 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
PL1759001T3 (pl) * 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
WO2005123142A1 (en) 2004-06-10 2005-12-29 Abraxis Bioscience, Inc. A method using inorganic nanoparticles as non-viral vectors for gene therapy
EP2573185A3 (en) 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use
DE102005023993A1 (de) 2005-05-20 2006-11-23 TransMIT Gesellschaft für Technologietransfer mbH Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge
GB0702695D0 (en) 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
DK2662448T3 (en) * 2007-05-11 2017-03-20 Alexion Pharma Inc Bone-targeted alkaline phosphatase, kits and methods for its use
US20090098055A1 (en) * 2007-08-23 2009-04-16 Intrexon Corporation Methods and Compositions for Diagnosing Disease
ES2374245B1 (es) 2010-08-02 2012-12-26 Universidad Castilla La Mancha Vectores no virales para terapia génica.
ES2374243B1 (es) 2010-08-02 2012-12-26 Universidad Castilla-La Mancha Vectores no virales para terapia génica.
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
CN103316356B (zh) 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
GB201220119D0 (en) 2012-11-08 2012-12-26 Univ Cork Vector
WO2016007873A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
FR3024464A1 (fr) 2014-07-30 2016-02-05 Centre Nat Rech Scient Ciblage de vecteurs integratifs non-viraux dans les sequences d'adn nucleolaires chez les eucaryotes
JP6787894B2 (ja) * 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
BR112021009913A2 (pt) * 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica

Also Published As

Publication number Publication date
JP2023540098A (ja) 2023-09-21
CA3190513A1 (en) 2022-03-10
KR20230117327A (ko) 2023-08-08
WO2022051555A3 (en) 2022-04-14
US20240150737A1 (en) 2024-05-09
WO2022051555A2 (en) 2022-03-10
EP4203989A2 (en) 2023-07-05
CN116848146A (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
US20240150737A1 (en) Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
ES2992295T3 (es) Composiciones potenciadoras de Vcn y métodos de uso de las mismas
US7423139B2 (en) High level expression of recombinant human erythropoietin having a modified 5′-UTR
KR102011532B1 (ko) 개선된 바이러스 형질도입을 위한 화합물
AU2012267512B2 (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
KR101958612B1 (ko) 개선된 유전자 치료 방법
US11813316B2 (en) Lentiviral vector for treating hemoglobin disorders
US20220323612A1 (en) Gene therapy of neuronal ceroid lipofuscinoses
US11326183B2 (en) VCN enhancer compositions and methods of using the same
US20220339296A1 (en) Gene therapy for mucopolysaccharidosis, type i
KR101966057B1 (ko) 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도
US20200071721A1 (en) Gene therapy for mucopolysaccharidosis, type ii
CN113544279A (zh) 包含芳基硫酸酯酶a的重组载体及其在用于治疗异染性脑白质营养不良的干细胞治疗中的用途
HK40002130B (en) Vcn enhancer compositions and methods of using the same
Scaife Truncated Cell Surface Markers Fused with Mutant Human Tmpk: Versatile Cell Fate Control Safety Cassettes for Lentiviral Vector Mediated Correction of Fabry Disease